SCHEMBL3877443

SCHEMBL3877443

NC1=NC(F)([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)N=C2N=CN=C12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.33
LMNA P02545 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MTOR P42345 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TP53 P04637 2/20 0.32
THRB P10828 1/20 0.32
MDM2 Q00987 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
POLB P06746 1/20 0.32
GMNN O75496 1/20 0.32
NFKB1 P19838 1/20 0.32
DNMT1 P26358 1/20 0.32
THPO P40225 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
BLM P54132 1/20 0.32
HBB P68871 1/20 0.32
PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873819 1.00 PNP (0.33) PNPLMNASMN1; SMN2MTORALDH1A1
Phosphoric Acid SCHEMBL3691841 0.94 PNP (0.32) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL6886933 0.84 PNP (0.33) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL11134890 0.73 PNP (0.38) PNPLMNASMN1; SMN2MTORALDH1A1
SCHEMBL851105 0.56 LGALS1 (0.44) MEN1KMT2A
SCHEMBL29114805 0.56 LGALS1 (0.40) MEN1KMT2A
SCHEMBL10353319 0.56 LGALS1 (0.40) MEN1KMT2A
SCHEMBL31601489 0.56 LGALS1 (0.40) MEN1KMT2A
SCHEMBL29114803 0.56 LGALS1 (0.40) MEN1KMT2A
SCHEMBL24243426 0.54 LGALS1 (0.59) LMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107109458-B Cell-based defibrotide potency assay 真蒂奥姆责任有限公司 2021-10-26 CN disclosed
EP-2107909-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS IDENIX Pharmaceuticals, Inc. (US) 2009-10-14 EP disclosed
WO-2008082602-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS IDENIX PHARMACEUTICALS, INC. (US) 2008-07-10 WO disclosed
EP-1439220-B1 Immobilized biocatalysts usable for the manufacture of natural nucleosides and modified analogues through enzymatic transglycosylation reactions ADORKEM TECHNOLOGY SPA (IT) 2007-08-22 EP disclosed
US-20040142438-A1 Novel immobilized biocatalysts usable for the production of natural nucleosides and modified analogues by enzymatic transglycosylation reactions KERYOS SPA (IT) 2004-07-22 US disclosed
EP-1439220-A1 Immobilized biocatalysts usable for the manufacture of natural nucleosides and modified analogues through enzymatic transglycosylation reactions Keryos Spa (IT) 2004-07-21 EP disclosed